From PsychonautWiki
Jump to: navigation, search
Summary sheet: AL-LAD
Molecular structure of AL-LAD
Chemical Nomenclature
Common names AL-LAD, Aladdin
Substitutive name 6-Allyl-6-nor-lysergic acid diethylamide
Systematic name (6aR,9R)-N,N-Diethyl-7-(prop-2-en-1-yl)-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 20 - 50 µg
Light 50 - 100 µg
Common 100 - 225 µg
Strong 225 - 350 µg
Heavy 350 µg +
Total 7 - 10 hours
Onset 20 - 60 minutes
Come up 30 - 60 minutes
Peak 2.5 - 5 hours
Offset 2 - 3 hours
After effects 2 - 18 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

6-Allyl-6-nor-lysergic acid diethylamide (also known as N-allyl-nor-lysergic acid N,N-diethylamide,[1] N-allyl-nor-LSD,[1] or commonly as AL-LAD[1]) is a novel psychedelic substance of the lysergamide chemical class that produces LSD-like psychedelic effects when administered. It is a closely related structural analog of LSD and is reported to produce very similar subjective effects.

AL-LAD was first investigated in 1984 by Andrew J. Hoffman and David Nichols as part of a series of LSD analogs, which also included ETH-LAD and PRO-LAD.[2] Its activity in humans was later documented by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"), in which it is described as "considerably less dramatic".[3] It is thought to either be equally or moderately less potent than LSD itself, with an active dose reported at between 75 and 150 micrograms.

Anecdotal reports indicate that it has subtly different effects to LSD. It is often described as being more visually-oriented but with a less introspective headspace. It also has a moderately shorter duration and is generally considered to be a less anxiety-provoking and "challenging" version of LSD. That is, until the strong dose range is reached, in which their effects are reported to largely converge.

Very little data exists about the pharmacological properties, metabolism, and toxicity of AL-LAD, and it has a relatively brief history of human usage. First appearing on the research chemicals market in 2013,[4] it has been commonly marketed alongside lysergamides such as 1P-LSD, ALD-52 and ETH-LAD as a legal, grey-market alternative to LSD. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent, long-lasting, and unstudied hallucinogenic substance with the proper amount of precaution and harm reduction practices if choosing to use it.



AL-LAD, or 6-allyl-6-nor-lysergic acid diethylamide, is a semisynthetic alkaloid of the lysergamide family. AL-LAD is a structural analog of lysergic acid, with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an ergoline derivative, and has overlapping tryptamine and phenethylamine groups embedded within it (although it is principally classed as a tryptamine).

AL-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). Unlike LSD, AL-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton, this is represented by the nor- prefix. Instead, AL-LAD is substituted at R6 with an allyl group comprised of a methylene bridge bound to a vinyl substituent. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound.


AL-LAD is a chiral compound with two stereocenters at R5 and R8. AL-LAD, also called (+)-D-AL-LAD, has an absolute configuration of (5R, 8R). The three other stereoisomers of AL-LAD do not have psychoactive properties.[5]


Further information: Serotonergic psychedelic

This compound likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from AL-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

AL-LAD shares many common traits with its parent compound LSD; in humans it appears to be roughly equal (if slightly less) in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable - perhaps due to being catabolised more readily). In rats, however, AL-LAD was measured to be around twice the potency of LSD,[2] although anecdotal reports by humans have reported to be about equipotent if not slightly less potently psychoactive as LSD.

Subjective effects

While its subjective effects largely overlap with those of LSD, AL-LAD is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety. Many users have proposed that this compound could potentially serve as an effective introductory psychedelic, alongside other shorter-lasting and manageable psychedelics like 2C-B or 4-HO-MET.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Experience reports

There are currently 2 anecdotal reports which describe the effects of this compound within our experience index.

Additional experience reports can be found here:


  • Cannabis - When used in combination with cannabis, both the visual and cognitive effects of AL-LAD can be intensified and extended with extreme efficiency. This should be used with extreme caution if one is not experienced with psychedelics as this can also amplify the anxiety, confusion and psychosis producing aspects of cannabis significantly.
  • Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of LSD have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations, and corresponding confusion which can spontaneously manifest as delusions and psychosis.
  • MDMA - When used in conjunction with MDMA, the physical and cognitive effects of MDMA are amplified. The visual, physical and cognitive effects of AL-LAD are also intensified with an overwhelming euphoric pleasure manifested through uniquely pleasurable body highs and headspaces, and uniquely colorful and awe-inspiring visuals. The synergy between these substances is unpredictable, and it is best to start with markedly lower dosages than one would take for both substances individually. Additionally, users should be aware that there are reasons to believe that this combination may result in unforeseen neurotoxic effects, so a strong sense of caution and independent research are highly advised if one decides to experiment with this combination.[citation needed]
  • Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration and nausea and physical fatigue which can negatively affect a trip if taken in moderate to high dosages. This combination is, however, reasonably safe in low doses and can often "take the edge off" a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit in a more physically distressing way.
  • Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of an AL-LAD trip. They are very efficient at stopping "bad trips" at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
  • Psychedelics - When used in combination with other psychedelics, each substance's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with significantly lower dosages than one would take for either substance individually.

Toxicity and harm potential

The toxicity and long-term health effects of recreational AL-LAD use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because AL-LAD is a research chemical with very little history of human usage.

Anecdotal evidence from those who have tried AL-LAD suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Similar to other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute AL-LAD exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, AL-LAD is able to be considered non-addictive, with an extremely low toxicity relative to dose.[6] It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute AL-LAD exposure.

However, as with LSD and psychedelics in general, it is possible that AL-LAD can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Tolerance and addiction potential

Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, AL-LAD is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of AL-LAD are built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). AL-LAD presents cross-tolerance with all psychedelics, meaning that after the use of AL-LAD all psychedelics will have a reduced effect.

Owing to its activity at the 5-HT2A receptor, AL-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of AL-LAD all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.



This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • International - AL-LAD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.
  • Austria: AL-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.[citation needed]
  • Latvia: AL-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.[8]
  • Switzerland: 21 additional chemicals were added to the list of illegal substances including AL-LAD in December 2015.[9]
  • Sweden: Following its sale as a designer drug, AL-LAD was made illegal in Sweden on 26 January 2016.[10]
  • United Kingdom: As of January 7th, 2015, AL-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.[11]
  • United States: AL-LAD is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.

See also

External links


  • Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255.
  • Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409.
  • Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
  • Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.


  1. 1.0 1.1 1.2 National Center for Biotechnology Information. PubChem Compound Database; CID=44457803, (accessed May 5, 2017).
  2. 2.0 2.1 Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255.
  3. | Erowid Online Books : "TiHKAL" - 1# AL-LAD
  4. Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., ... & Halberstadt, A. L. (2016). Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD). Drug Testing and Analysis, 8(9), 891-902.
  6. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The Pharmacology of Lysergic Acid Diethylamide: A Review, 14, 295–314.
  7. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  8. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) |
  10. (in Swedish) Folkhälsomyndigheten. |
  11. ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.